

*add
lower*

which makes the molecule at least lack IgE binding capacity, and
(ii) a Phl p6 molecule having a C-terminal deletion which makes
the molecule at least lack IgE binding capacity, wherein the
molecules of (i) and (ii) together span the complete sequence of
Phl p6.

Please add the following new claims:

1
~~15~~. A hypoallergenic polypeptide consisting of an amino
acid sequence of SEQ ID NO: 20.

E2

16. A hypoallergenic immunogenic composition comprising a
hypoallergenic polypeptide consisting of an amino acid sequence of
SEQ ID NO: 20 and a pharmaceutically acceptable carrier.

17. The composition of claim 6, wherein the molecule having
a N-terminal deletion is a polypeptide comprising an amino acid
sequence of SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20.

2 ~~18~~. A hypoallergenic polypeptide consisting of an amino acid
sequence of SEQ ID NO: 21.

19. A hypoallergenic immunogenic composition comprising a
hypoallergenic polypeptide consisting of an amino acid sequence of
SEQ ID NO: 21 and a pharmaceutically acceptable carrier.

20. The composition of claim 6, wherein the molecule having a C-terminal deletion is a polypeptide comprising an amino acid sequence of SEQ ID NO: 21.

EJ
Concl
21. The composition of claim 6, wherein the molecule having a N-terminal deletion is a polypeptide comprising an amino acid sequence of SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20; and wherein the molecule having a C-terminal deletion is a polypeptide comprising an amino acid sequence of SEQ ID NO: 21.--
